Document is current
Any future updates will be listed below
-
Authors
Morris, Rosie https://orcid.org/0000-0002-0290-6688
Martini, Douglas N.
Ramsey, Katrina
Kelly, Valerie E.
Smulders, Katrijn
Hiller, Amie
Chung, Kathryn A.
Hu, Shu-Ching
Zabetian, Cyrus P. https://orcid.org/0000-0002-7739-4306
Poston, Kathleen L. https://orcid.org/0000-0003-3424-7143
Mata, Ignacio F. https://orcid.org/0000-0003-1198-0633
Edwards, Karen L.
Lapidus, Jodi
Cholerton, Brenna https://orcid.org/0000-0002-2139-987X
Montine, Thomas J.
Quinn, Joseph F.
Horak, Fay
- License Information
-
More Information
Article History
Received: 12 October 2021
Accepted: 26 May 2022
First Online: 20 June 2022
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests; V.E.K. has received grant support from the report’s grants from NIH, Department of Veterans Affairs, and University of Washington and is an external advisor for projects by Sage Bionetworks. B.C. is supported by grants from the NIH. C.P.Z. is supported by grants from the NIH, Department of Veterans Affairs, and the American Parkinson Disease Association. K.P. has received grants from the NIH, clinical trial funded by Sanofi, and consulting for Allergan. K.L.E. has received grants from the NIH. T.J.M. has received grants from the NIH and Farmer Family Foundation. J.F.Q. receives compensation for conducting clinical trials for Roche, Sanofi, Abbvie, and member of DSMB for Retrophin pharmaceuticals. F.H. has a significant financial interest in APDM, a division of Clario Int, a company that may have a commercial interest in the results of this research and technology. This potential institutional and individual conflict has been reviewed and managed by OHSU. R.M., D.N.M., K.R., K.S., A.H., K.A.C., S.C.H., I.M., and J.L. have nothing to declare.
